Raloxifene Augmentation in Patients With a Schizophrenia Spectrum Disorder (RAPSODI)
Raloxifene Augmentation in Patients With a Schizophrenia Spectrum Disorder to Reduce Symptoms and Improve Cognition
Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Listed as NCT03043820, this PHASE3 trial focuses on Psychosis NOS and Schizoaffective Disorder and remains completed. Sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), it has been updated 9 times since 2016, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Nov 2021 — Jul 2024 [monthly]
Completed PHASE3
Status: Recruiting → Completed
-
Jan 2021 — Nov 2021 [monthly]
Recruiting PHASE3
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE3
▶ Show 4 earlier versions
-
Sep 2020 — Nov 2020 [monthly]
Recruiting PHASE3
-
Jul 2019 — Sep 2020 [monthly]
Recruiting PHASE3
-
Jun 2018 — Jul 2019 [monthly]
Recruiting PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE3
First recorded
Aug 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Altrecht GGZ
- GGZ Centraal
- GGZ Eindhoven
- Iris Sommer
- Julius Center
- Reinier van Arkel Group
- Rudolf Magnus Institute - University of Utrecht
- Ziekenhuis Netwerk Antwerpen (ZNA)
For direct contact, visit the study record on ClinicalTrials.gov .